Results from a Phase 2 trial evaluating nivolumab in combination with ivosidenib for IDH1 mutant advanced solid tumors and gliomas were posted on 2025-02-06. The study, which included 15 participants, reported 0 dose-limiting toxicities, indicating a favorable safety profile for the concurrent dosing regimen.
Background
The trial investigated the combination of ivosidenib and nivolumab in patients diagnosed with advanced solid tumors or gliomas that carried an IDH1 mutation. These specific mutations are a focus for targeted therapeutic approaches in oncology.
Trial design
This completed Phase 2 study (NCT04056910) enrolled 15 participants. The trial focused on individuals with advanced solid tumors or enhancing gliomas that carried an IDH1 mutation. The investigation aimed to assess the response to treatment, progression-free survival, overall survival, and the safety profile of ivosidenib administered concurrently with nivolumab.
Key results
Key results from the trial for the concurrent dosing of ivosidenib and nivolumab included:
- The occurrence of Dose Limiting Toxicity (DLT) was observed in 0 participants.
- Six Month Progression-Free Survival (PFS6) was reported in 20 percentage of participants.
- For Best Overall Response, 1 participant achieved a response.
- Adverse Events Related to Treatment were observed in various participants, with counts of 2, 1, 2, 3, 4, 4, 1, and 2 participants across different events.
What this means
The finding of 0 dose-limiting toxicities suggests that the concurrent administration of ivosidenib and nivolumab may have a manageable safety profile in this patient population. While the Best Overall Response was observed in 1 participant and the Six Month Progression-Free Survival was 20 percent, these initial results provide insights into the activity and tolerability of this combination therapy for IDH1 mutant advanced solid tumors and gliomas. Further research would be needed to fully understand the efficacy and long-term benefits.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04056910, titled "Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors," were posted on 2025-02-06 on clinicaltrials.gov.